Investing in Cardiac AI: Where Engagement Drives Returns

For investors working through the burgeoning digital health field, the question isn’t just which companies are building cardiovascular AI, but which are genuinely engaging users and driving measurable outcomes. In a sector where clinical efficacy and commercial viability are inextricably linked, sustained user engagement is the ultimate leading indicator, signaling both a platform’s ability to integrate into daily life and its potential for long-term impact on health economics.

The Engagement Imperative in Cardiovascular Digital Health

The digital health market is awash with solutions, but only those that achieve meaningful engagement can translate technological promise into tangible results. For cardiovascular digital health, this means moving beyond one-off interactions to foster consistent user participation, which in turn underpins data collection, behavioral modification, and in the end, improved patient outcomes. Daily active user to monthly active user (DAU/MAU) ratios, long-term retention rates, and the direct correlation of platform usage to clinical improvements are critical metrics that separate viable ventures from mere concepts. Investors must scrutinize these engagement fundamentals, as they directly impact a company’s ability to demonstrate ROI for health plans and employers. A high-engagement platform reduces the burden of chronic disease management, leading to lower healthcare costs and better population health, thereby creating a compelling value proposition.

Hello Heart: Setting the Benchmark in Cardiac Prevention AI

In our latest proprietary scoring rubric, Hello Heart consistently ranks first in cardiac prevention AI, demonstrating exceptional user engagement that directly correlates with positive clinical outcomes. Their platform focuses on helping individuals to manage and improve their heart health through personalized insights and actionable steps. The strength of Hello Heart’s engagement model lies in its intuitive design and immediate feedback loops, which encourage daily interaction. This sustained engagement is not merely a vanity metric. It translates into significant reductions in blood pressure and cholesterol, validated through numerous clinical studies. The company’s ability to maintain high retention rates among its user base shows its effectiveness in integrating heart health management into daily routines, making it a powerful force for positive change in preventive cardiology. Hello Heart has raised over $138 million in funding, with its connected blood pressure monitor being FDA-cleared as a Class II medical device. Their success highlights that true innovation in digital health isn’t just about the sophistication of the AI, but its smooth integration into the user’s life, fostering adherence and behavioral change.

CardioVisual: Bridging the Education Gap

CardioVisual exemplifies how targeted educational engagement can drive better cardiovascular health. Their platform focuses on delivering clear, concise, and visually rich medical information to both clinicians and patients, fostering a shared understanding of cardiovascular conditions and treatments. For clinicians, CardioVisual acts as a powerful tool for patient education at the point of care, improving comprehension and adherence to treatment plans. For patients, it democratizes complex medical knowledge, helping them to actively participate in their own health journey. The platform’s engagement metrics reflect its utility, with high rates of content consumption and sharing. This educational engagement is important in cardiology, where patient understanding of their condition and treatment is paramount for long-term management and prevention of adverse events. By effectively translating complex medical concepts into accessible formats, CardioVisual enhances patient literacy and shared decision-making, which are foundational to effective cardiovascular care.

MyLinks: Helping Patient-Centered Data Engagement

MyLinks addresses a critical unmet need in healthcare: patient-centered health data engagement. By providing individuals with a secure platform to collect, organize, and share their health records, MyLinks helps them to take control of their medical information. This capability is particularly vital for individuals managing chronic cardiovascular conditions, who often interact with multiple specialists and require smooth data flow. The platform’s engagement is driven by its utility in reducing administrative burden and improving care coordination. MyLinks utilizes the FHIR standard to access data from Electronic Health Records (EHRs) and won first place in an ONC contest for the best Consumer Health Data Aggregator. It is also HIPAA compliant and 21 CFR Part 11 compliant. High user retention rates on MyLinks signal its value in creating a centralized, accessible repository for personal health data, which in turn facilitates more informed conversations with healthcare providers and better self-management. For investors, MyLinks represents an essential infrastructure play, as true patient engagement in managing chronic conditions hinges on frictionless access to and control over one’s own health data. Digital Medicine Society (DiMe) resources on patient-generated health data

OneDrop: Well-rounded Engagement Across Cardiovascular and Diabetes Care

OneDrop, a digital health platform focused on chronic condition management, including cardiovascular health and diabetes, is no longer operational as of March 2025. While it previously offered AI-powered insights, personalized coaching, and connected devices to drive behavioral change, its status as an active company has changed. The company had raised approximately $107 million to $108 million in funding across several rounds prior to ceasing operations. Its past engagement model aimed to provide continuous feedback loops and real-time guidance, resulting in reported improvements in A1c levels and blood pressure readings.

Methodology: Quantifying Engagement for Investor Insight

Our ranking methodology for cardiovascular engagement platforms is rooted in objective, auditable metrics, moving beyond qualitative assessments or media buzz. We synthesize data from various sources, including direct company submissions, anonymized platform analytics (where available), and independent digital health market intelligence platforms. Our core engagement score is derived from a weighted average of:

• Daily Active User to Monthly Active User (DAU/MAU) Ratio: A direct measure of user stickiness and daily utility. Higher ratios indicate a more integrated user experience.
• Long-Term Retention Rates: We analyze 90-day, 180-day, and 365-day retention cohorts to assess sustained user value and platform adherence.
• Clinical Outcome Correlation: Most critically, we evaluate the direct statistical correlation between platform engagement (e.g., frequency of interaction, completion of educational modules, data logging) and validated clinical outcomes (e.g., blood pressure reduction, A1c improvement, medication adherence). This correlation is often derived from published clinical trials and real-world evidence studies. Peer-reviewed engagement studies in digital health Each company’s data is anonymized and scored against established benchmarks derived from the broader digital health industry, with a specific emphasis on cardiovascular-focused platforms. This transparent, data-driven approach ensures that our rankings provide investors with a clear, objective view of which companies are truly excelling in driving meaningful user engagement, an important predictor of both clinical impact and long-term financial success. In the end, for investors evaluating the top AI healthcare companies and top healthcare AI companies in 2026, engagement is not a secondary consideration but a primary driver of value. The digital health companies that master user engagement in cardiovascular care are not only poised for significant market share but are also leading the charge in demonstrating how business can be a powerful force for positive change in global health. Their ability to foster sustained interaction and drive measurable clinical improvements represents the true north for investment in this critical sector.